Broad antibody mediated cross-neutralization and preclinical immunogenicity of new codon-optimized HIV-1 clade CRF02_AG and G primary isolates

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Agwale, Simon M ^a,b   Forbi, Joseph C ^a,b   Notka, Frank ^c   Wrin, Terri ^d   Wild, Jens ^e   Wagner, Ralf ^c,e   Wolf, Hans ^e  

^a Clinical Virology Laboratory   (Nigeria)

^b Frederick Innovative Technology Center   (United States)

^c Geneart AG   (Germany)

^d MONOGRAM BIOSCIENCES   (United States)

^e UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; DNA; GAG PROTEIN; GLYCOPROTEIN GP 140; NEUTRALIZING ANTIBODY; PLASMID DNA; TRANSACTIVATOR PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CLADISTICS; CODON; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MOLECULAR CLONING; MOUSE; NIGERIA; NONHUMAN; SYNTHESIS; VIRUS ISOLATION; VIRUS NEUTRALIZATION; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CLASSIFICATION; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETICS; IMMUNOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SERODIAGNOSIS; TUMOR CELL LINE;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS;

AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; CELL LINE, TUMOR; CODON; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HIV ANTIBODIES; HIV-1; HUMANS; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES, CYTOTOXIC;

EID: 79961157901     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023233     Document Type: Article

References (40)

1. UNAIDS (2009) 2009 AIDS epidemic update.
2. Haigwood NL, Zolla-Pazner S, (1998) Humoral immunity to HIV, SIV, and SHIV. AIDS 12 (Suppl A): S121-132.
3. Connor RI, Korber BT, Graham BS, Hahn BH, Ho DD, et al. (1998) Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J Virol 72: 1552-1576.
4. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, et al. (2005) Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 191: 654-665.
5. Russell ND, Graham BS, Keefer MC, McElrath MJ, Self SG, et al. (2007) Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. J Acquir Immune Defic Syndr 44: 203-212.
6. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, et al. (2006) Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 194: 1661-1671.
7. UNAIDS (2009) Largest ever HIV vaccine trial results very encouraging.
8. Agwale SM, Zeh C, Robbins KE, Odama L, Saekhou A, et al. (2002) Molecular surveillance of HIV-1 field strains in Nigeria in preparation for vaccine trials. Vaccine 20: 2131-2139.
9. Agwale SM, Zeh C, Paxinos E, Odama L, Pienazek D, et al. (2006) Genotypic and phenotypic analyses of human immunodeficiency virus type 1 in antiretroviral drug-naive Nigerian patients. AIDS Res Hum Retroviruses 22: 22-26.
10. Meloni ST, Kim B, Sankale JL, Hamel DJ, Tovanabutra S, et al. (2004) Distinct human immunodeficiency virus type 1 subtype A virus circulating in West Africa: sub-subtype A3. J Virol 78: 12438-12445.
11. Carr JK, Torimiro JN, Wolfe ND, Eitel MN, Kim B, et al. (2001) The AG recombinant IbNG and novel strains of group M HIV-1 are common in Cameroon. Virology 286: 168-181.
12. Carr JK, Wolfe ND, Torimiro JN, Tamoufe U, Mpoudi-Ngole E, et al. (2010) HIV-1 recombinants with multiple parental strains in low-prevalence, remote regions of Cameroon: evolutionary relics? Retrovirology 7: 39.
13. Schultz AM, Bradac JA, (2001) The HIV vaccine pipeline, from preclinical to phase III. AIDS 15 (Suppl 5): S147-158.
14. Kent SJ, Cooper DA, Chhi Vun M, Shao Y, Zhang L, et al. (2010) AIDS vaccine for Asia Network (AVAN): expanding the regional role in developing HIV vaccines. PLoS Med 7: e1000331.
15. Taiwo OO, Hassan Z, (2010) The impact of Highly Active Antiretroviral Therapy (HAART) on the clinical features of HIV- related oral lesions in Nigeria. AIDS Res Ther 7: 19.
16. Haigwood NL, Stamatatos L, (2003) Role of neutralizing antibodies in HIV infection. AIDS 17 (Suppl 4): S67-71.
17. Stamatatos L, Morris L, Burton DR, Mascola JR, (2009) Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med 15: 866-870.
18. Petropoulos CJPN, Limoli KI, Lie YS, Wrin T, Huang W, Tian H, Smith D, Winslow GA, Capon DJ, Whitcomb JM, (2000) A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1 Antimicrob Agents Chemother 44: 920-928.
19. Graham FL, Smiley J, Russell WC, Nairn R, (1977) Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36: 59-74.
20. Ponten J, Macintyre EH, (1968) Long term culture of normal and neoplastic human glia. Acta Pathol Microbiol Scand 74: 465-486.
21. Richman DD, Wrin T, Little SJ, Petropoulos CJ, (2003) Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 100: 4144-4149.
22. Wild J, Bieler K, Kostler J, Frachette MJ, Jeffs S, et al. (2009) Preclinical evaluation of the immunogenicity of C-type HIV-1-based DNA and NYVAC vaccines in the Balb/C mouse model. Viral Immunol 22: 309-319.
23. Giaccone G, Battey J, Gazdar AF, Oie H, Draoui M, et al. (1992) Neuromedin B is present in lung cancer cell lines. Cancer Res 52: 2732s-2736s.
24. Graf M, Bojak A, Deml L, Bieler K, Wolf H, et al. (2000) Concerted action of multiple cis-acting sequences is required for Rev dependence of late human immunodeficiency virus type 1 gene expression. J Virol 74: 10822-10826.
25. Deml L, Bojak A, Steck S, Graf M, Wild J, et al. (2001) Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein. J Virol 75: 10991-11001.
26. Bojak A, Wild J, Deml L, Wagner R, (2002) Impact of codon usage modification on T cell immunogenicity and longevity of HIV-1 gag-specific DNA vaccines. Intervirology 45: 275-286.
27. UNAIDS (2007) Report on the global HIV/AIDS epidemic. Sub-Saharan Africa AIDS epidemic update Regional Summary 2007. 18.
28. Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H, et al. (1998) Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 351: 1682-1686.
29. Ramos A, Hu DJ, Nguyen L, Phan KO, Vanichseni S, et al. (2002) Intersubtype human immunodeficiency virus type 1 superinfection following seroconversion to primary infection in two injection drug users. J Virol 76: 7444-7452.
30. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, et al. (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326: 285-289.
31. Carrow EW, Vujcic LK, Glass WL, Seamon KB, Rastogi SC, et al. (1991) High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas. AIDS Res Hum Retroviruses 7: 831-838.
32. Vogel T, Kurth R, Norley S, (1994) The majority of neutralizing Abs in HIV-1-infected patients recognize linear V3 loop sequences. Studies using HIV-1MN multiple antigenic peptides. J Immunol 153: 1895-1904.
33. Kwong PD, Doyle ML, Casper DJ, Cicala C, Leavitt SA, et al. (2002) HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420: 678-682.
34. Frost SD, Trkola A, Gunthard HF, Richman DD, (2008) Antibody responses in primary HIV-1 infection. Curr Opin HIV AIDS 3: 45-51.
35. Agwale SM, Shata MT, Reitz MS Jr, Kalyanaraman VS, Gallo RC, et al. (2002) A Tat subunit vaccine confers protective immunity against the immune-modulating activity of the human immunodeficiency virus type-1 Tat protein in mice. Proc Natl Acad Sci U S A 99: 10037-10041.
36. Andre S, Seed B, Eberle J, Schraut W, Bultmann A, et al. (1998) Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J Virol 72: 1497-1503.
37. Bojak A, Deml L, Wagner R, (2002) The past, present and future of HIV-vaccine development: a critical view. Drug Discov Today 7: 36-46.
38. Wayne CK, Berkley SF, (2010) The renaissance in HIV vaccine development-future directions. N Engl J Med 363: e7.
39. Yu XG, Addo MM, Rosenberg ES, Rodriguez WR, Lee PK, et al. (2002) Consistent patterns in the development and immunodominance of human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T-cell responses following acute HIV-1 infection. J Virol 76: 8690-8701.
40. Rolland M, Heckerman D, Deng W, Rousseau CM, Coovadia H, et al. (2008) Broad and Gag-biased HIV-1 epitope repertoires are associated with lower viral loads. PLoS One 3: e1424.